10
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      Are you tired of sifting through news that doesn't interest you?
      Personalize your Karger newsletter today and get only the news that matters to you!

      Sign up

      • Record: found
      • Abstract: found
      • Article: found

      Interferon-β Treatment of Herpes Simplex Keratitis

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We tested a new preparation of interferon-β (IFN-β) to determine its efficacy and tolerability in the treatment of herpetic keratitis. The 20 patients admitted to the trial were selected from patients who had not received any previous treatment with virustatic agent; they were treated in a comparative, randomised open trial with eye drop containing IFN-β or iododesoxyuridine (10 vs. 10). Examination of the data show that 10 out of 10 patients treated with IFN-β respond positively to the treatment, furthermore it showed that IFN-β produce no local or general toxicity.

          Related collections

          Author and article information

          Journal
          OPH
          Ophthalmologica
          10.1159/issn.0030-3755
          Ophthalmologica
          S. Karger AG
          0030-3755
          1423-0267
          1986
          1986
          31 March 2010
          : 192
          : 1
          : 6-10
          Affiliations
          aGeneral Ophthalmic Division, Torino Eye Hospital (Head: Prof. A. Vannini), Turin, and bClinical Pharmacological Department I. F. Serono, Rome, Italy
          Article
          309604 Ophthalmologica 1986;192:6–10
          10.1159/000309604
          3703481
          d2241933-5069-44f1-a5e6-3464a802f9ce
          © 1986 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          : 16 July 1985
          : 28 July 1985
          Page count
          Pages: 5
          Categories
          Original Paper

          Vision sciences,Ophthalmology & Optometry,Pathology
          Keratitis dendritica,Interferon treatment,Herpes simplex keratitis

          Comments

          Comment on this article